Kisspeptin-10

Kisspeptin-10 is a ten-amino-acid fragment of a larger protein encoded by the KISS1 gene. Its discovery is one of the more unusual stories in endocrinology: the gene was first identified in cancer research as a suppressor of metastasis, and named after the town where it was found. Its role in reproduction emerged years later and from a different direction entirely.

That second discovery came from human genetics. Families were identified in which puberty never began, and the common factor was a non-functioning receptor — the one kisspeptin binds. The finding established that this peptide sits at the very top of the reproductive hormone cascade: without the signal, the entire axis below it stays silent.

This is what makes it a distinctive research compound. Most peptides act somewhere in the middle of a control system. Kisspeptin acts at the point where the system is switched on, upstream of the hormone that governs everything downstream, which is why it is described as the gatekeeper of reproductive function.

• The top of the cascade: It acts on the neurons that release GnRH, the hormone controlling the pituitary's reproductive output. Intervening above that point is a different experiment from intervening anywhere below it.

• Human genetics established the role: Loss-of-function mutations in its receptor prevent puberty in people. Evidence of that kind — a natural experiment in humans — is considerably stronger than most peptide research rests on.

• How puberty begins: What restarts a dormant reproductive axis in adolescence is a long-standing question, and kisspeptin signalling is the leading answer. The peptide is the main tool for investigating it.

• Two origins, one gene: The same gene was found independently in metastasis research and in reproductive biology. Why one protein carries both roles remains genuinely unresolved and is studied in its own right.

Reproductive hormones are controlled by a chain of three signals. Neurons in the hypothalamus release GnRH in pulses; GnRH instructs the pituitary to release LH and FSH; those in turn act on the gonads. Each step depends on the one above, and the whole chain is governed by the pattern of pulses at the top — a steady signal produces a different result from a rhythmic one.

Kisspeptin acts one level above even that. Its neurons contact the GnRH neurons directly and determine when they fire, which places it at the true origin of the cascade. The receptor it binds, KISS1R, is what those GnRH neurons carry, and the human mutations that silence it silence everything downstream.

The reason this arrangement exists appears to be integration. Kisspeptin neurons receive input about energy stores, sex hormone concentrations and daily rhythm, and translate it into a decision about whether reproduction should proceed. The peptide is not simply a switch — it is where several kinds of information are combined before the system is allowed to run.

The evidence for the core role is strong and comes from three independent directions: human genetics, animal models and controlled human administration studies in which kisspeptin produced measurable LH release. Its position at the top of the reproductive axis is established rather than proposed, which distinguishes it sharply from most compounds in this catalogue.

Clinical use is exploratory: trials have examined it in fertility assessment and as a diagnostic probe, none has reached approval, and it is supplied for laboratory research only. The biology under it is unusually firm, resting on human genetics as well as animal work, which is what makes it the tool of choice for intervening at the top of the reproductive cascade.

Kisspeptin belongs to a different axis from the rest of this category, and that is the most useful thing to say about it. CJC-1295 and Ipamorelin act on the pituitary within the growth hormone system; this peptide acts above the pituitary within the reproductive one.

They are grouped because both are hypothalamic–pituitary questions and the techniques used to study them overlap. Oxytocin belongs to the same neuroendocrine territory and is the clearest illustration of how differently two peptides in it can be evidenced. The hormones, the receptors and the downstream consequences do not, and conflating the two axes is a common error in secondary writing about peptides.